SAVA, GIANNI
 Distribuzione geografica
Continente #
NA - Nord America 19.954
EU - Europa 10.147
AS - Asia 4.750
SA - Sud America 609
AF - Africa 78
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 14
Totale 35.582
Nazione #
US - Stati Uniti d'America 19.862
UA - Ucraina 1.906
SE - Svezia 1.862
SG - Singapore 1.688
CN - Cina 1.388
DE - Germania 1.244
PL - Polonia 1.138
IT - Italia 991
HK - Hong Kong 988
RU - Federazione Russa 674
FI - Finlandia 616
BR - Brasile 528
GB - Regno Unito 506
TR - Turchia 354
BG - Bulgaria 304
IE - Irlanda 291
FR - Francia 265
NL - Olanda 110
IN - India 72
CA - Canada 55
CH - Svizzera 54
BD - Bangladesh 35
BE - Belgio 33
KR - Corea 31
EU - Europa 30
VN - Vietnam 28
AR - Argentina 26
AT - Austria 24
SA - Arabia Saudita 24
SN - Senegal 23
IQ - Iraq 19
MX - Messico 19
ES - Italia 17
RO - Romania 17
CL - Cile 15
VE - Venezuela 15
BA - Bosnia-Erzegovina 14
TH - Thailandia 14
CZ - Repubblica Ceca 13
EG - Egitto 13
PT - Portogallo 12
JP - Giappone 11
PK - Pakistan 11
RS - Serbia 11
ZA - Sudafrica 11
ID - Indonesia 10
UZ - Uzbekistan 10
DK - Danimarca 9
MA - Marocco 9
NZ - Nuova Zelanda 8
EC - Ecuador 7
GR - Grecia 7
IR - Iran 7
MY - Malesia 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
HR - Croazia 6
BO - Bolivia 5
CO - Colombia 5
GE - Georgia 5
HU - Ungheria 5
JO - Giordania 5
KZ - Kazakistan 5
NP - Nepal 5
TW - Taiwan 5
IL - Israele 4
JM - Giamaica 4
KE - Kenya 4
LT - Lituania 4
NG - Nigeria 4
SI - Slovenia 4
TN - Tunisia 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
DZ - Algeria 3
LB - Libano 3
OM - Oman 3
PE - Perù 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
DO - Repubblica Dominicana 2
ET - Etiopia 2
HN - Honduras 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GT - Guatemala 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 35.574
Città #
Woodbridge 2.449
Ann Arbor 2.360
Fairfield 1.902
Houston 1.682
Jacksonville 1.641
Chandler 1.266
Ashburn 1.208
Warsaw 1.114
Wilmington 1.109
Hong Kong 978
Singapore 955
Seattle 829
Cambridge 647
Princeton 574
Boardman 476
Beijing 411
Sofia 304
Columbus 290
Dublin 288
Izmir 277
Hefei 239
Moscow 227
Dearborn 217
Santa Clara 211
Trieste 175
Chicago 147
San Diego 135
Düsseldorf 109
Milan 108
Los Angeles 84
Munich 68
The Dalles 55
Falls Church 54
Verona 53
Kocaeli 51
Frankfurt am Main 47
Norwalk 47
Buffalo 46
Redwood City 46
Helsinki 44
Bern 43
Kunming 43
Bremen 41
Nanjing 41
Mestre 39
São Paulo 39
Phoenix 38
Guangzhou 34
Des Moines 32
Jinan 32
Shanghai 32
Salt Lake City 30
Brussels 29
Dakar 23
North Bergen 23
Seoul 23
Dallas 22
Turku 22
New York 21
Rio de Janeiro 21
Andover 19
San Francisco 18
Fuzhou 17
Tampa 17
Elk Grove Village 16
Nanchang 16
Ottawa 16
Vienna 16
Auburn Hills 15
Redmond 15
Shenyang 15
Zhengzhou 15
Dong Ket 14
Hangzhou 14
Hebei 14
Belo Horizonte 13
Dulles 13
London 13
Nuremberg 13
Sarajevo 13
Chennai 12
Chengdu 11
Fremont 11
Porto Alegre 11
Portsmouth 11
Riyadh 11
Brooklyn 10
Campinas 10
Detroit 10
Mountain View 10
Poplar 10
Toronto 10
Washington 10
Boston 9
Brasília 9
Changsha 9
Dhaka 9
Lauterbourg 9
Miami 9
Montreal 9
Totale 24.053
Nome #
The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects 575
Effects of Two Fullerene Derivatives on Monocytes and Macrophages 423
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 333
Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis 304
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 300
Chemical and Molecular Approach to Tumor Metastases 298
A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival 258
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 231
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. 226
New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. 218
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 210
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)(Im)]. 194
Antitumor action of mer-trichlorobis(dimethyl sulfoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma 194
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 191
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 191
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide 191
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results 190
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure 188
trans-Ru(II)dimethylsulfoxides: antineoplastic action on mouse tumors 180
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 180
Ruthenium(III) complexes as antineoplastic agents. 177
Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma 176
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy 176
Antitumor properties of ruthenium(II)-dimethylsulfoxide complexes in the Lewis lung carcinoma system 175
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review 175
Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii 174
Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. 173
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma 172
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 172
Tumor inhibition and effects on host survival time by rutheniumIII andrhodiumIII complexes with dimethylsulphoxide ligands. 171
Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs 171
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 171
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 170
Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity 170
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 166
Complessi trans di rutenio come agenti antineoplastici 165
Effects of trans-RuCl2 (DMSO)4 on B16 melanoma in mice. 163
Antineoplastic effects of mer-RuCl3(DMSO)2(NH3) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. 163
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 163
Biochemical and biological characteristics of leucocyte proteinase inhibitors. 163
Investigation on the oxidative N-demethylation of aryltriazenes in vitro 163
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 162
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 161
Na[trans-RuCl4(DMSO)(Im)]*2DMSO - antimetastatic ruthenium agent 161
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline 161
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes 161
Ruthenium complexes can target determinants of tumour malignancy 160
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms 160
Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. 159
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 158
Complessi di Rutenio con elevata attività antitumorale 156
Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice. 156
Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride 156
Antimetastatic action of the prostacyclin analog Iloprost in the mouse 155
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 154
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 154
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 154
Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells 154
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 154
Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A(imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate)ON KB Tumor cells. 153
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A 153
Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 153
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 152
Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK 151
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 151
Pharmacological aspects and therapeutic applications of lysozymes 150
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice 149
Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in theLewis lung carcinoma system. 148
Lysozyme induced recovery of the response to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma 148
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 147
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. 147
Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells 147
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties 147
Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice 147
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 146
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 146
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. 146
Methodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. 146
Evidence for host-mediated antitumor effects of lysozyme in mice bearing MCa mammary carcinoma 146
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 145
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA 145
Tumour metastatic potential after treatment with selective antimetastatic drugs 145
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 144
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 143
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 143
Neutral proteinase inhibitors and antimetastatic effects in mice. 142
Cis- and trans-dihalotetrakis(dimethylsulfoxide)Ruthenium(II) Complexes (RuX2(Me2SO)4; X = Cl, Br): Synthesis, Structure and Antitumor Activity 140
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 140
Mechanism of the antimetastatic action of N-diazoacetylglycinamide in mice bearing Lewis lung carcinoma. 140
Antimetastatic action and toxicity on healthy tissues ofNa[trans-RuCl4(DMSO)Im] in the mouse. 139
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. 139
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 139
Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes 139
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 139
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq 139
Antimetastatic action and toxicity on healty tissues of Na[trans-RuCl4(DMSO)Im] in the mouse. 138
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir 138
Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. 138
Effects of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. 138
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A 137
Totale 17.403
Categoria #
all - tutte 108.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.193


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.217 425 164 381 626 271 498 200 381 199 490 136 446
2021/20223.230 103 253 187 463 49 257 137 116 386 345 200 734
2022/20233.888 426 429 284 486 445 737 9 354 474 23 158 63
2023/20241.932 163 134 109 112 221 92 245 504 29 35 141 147
2024/20255.277 96 157 510 422 495 511 430 310 720 559 441 626
2025/2026785 785 0 0 0 0 0 0 0 0 0 0 0
Totale 36.287